SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

C214 - Multiple Sclerosis Overview II: Clinical Advances

Event Time: Thursday April 27, 2017 3:30 pm to 5:30 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s): Scott Newsome DO, FAAN
Description: It is extremely important for clinicians treating MS to enhance their knowledge base about the changing landscape of the MS disease-modifying therapies (DMTs). Making treatment decisions for an individual MS patient is a daunting task and the individualized patient benefit-risk assessment becomes increasingly difficult as new therapies emerge. Furthermore, if these therapies become available, clinicians need to have a full understanding of their benefit-risk profiles. Faculty will review the efficacy and safety profiles of current and late-stage emerging MS DMTs. It is equally challenging to define what constitutes optimal and suboptimal response to DMTs for an individual patient. Moreover, it is critical for clinicians to be able to recognize short-term clinical and paraclinical factors that may help identify patients at high risk for long-term disability. Faculty will review key considerations in MS clinical practice to address the above challenges in both didactic and case-based formats. This program complements C190: Multiple Sclerosis Overview: Basic and Translational Science and C201: Multiple Sclerosis Overview: Clinical Pearls, but covers independent topics.
Completion Message: Participants should feel more confident in prescribing and monitoring multiple sclerosis (MS) disease-modifying therapies (DMTs) as it relates to their efficacy and safety profiles along with develop a better understanding of key considerations in clinical practice. Participants will also become familiar with late-stage DMTs that have a strong potential of getting approved for use in MS. Participants should also be able to recognize what factors put an MS patient at risk for long-term disability and when to consider switching therapies.
CME Credits: 2
Core Competencies: Medical Knowledge, Patient Care

Program Speakers - Tentative

Start/End Time Title Faculty
3:30 PM - 4:30 PM The Expanding Armamentarium of Multiple Sclerosis Therapeutics Scott Newsome DO, FAAN 
4:30 PM - 5:30 PM Case-based Considerations in Clinical Practice for Multiple Sclerosis Myla Goldman MD, MSC 

Disclosures

Speaker Disclosure
Myla D. Goldman, MD, MSC Compensation from Genzyme and Novartis for consulting services and from Acorda Therapeutics, Biogen, Genzyme, and Novartis Pharmaceuticals for travel reimbursement. Institutional Consulting Contracts: Novartis, Biogen, Acorda (payment goes to UVA. Travel reimbursement to MDG when appropriate). Research support from Biogen, Novartis Pharmaceuticals, NMSS and NINDS.

Scott Douglas Newsome, DO, FAAN Dr. Newsome has received personal compensation for activities with Biogen Idec, Novartis, and Genzyme.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C97 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C107 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C121 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C135 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C146 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C161 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C174 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C223 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN

MEMBER LOG IN

Forgot Password?